Pay in 4 interest-free payments of $5.69 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
RegeneRx Biopharmaceuticals conducted randomized, double-blind, placebo-controlled Phase 1A and 1B studies of intravenous TB4 administration in healthy volunteers, finding the drug safe and well tolerated
Subcutaneous planning from a 50 mg vial reconstituted with 3.0 mL BAC water (~16.7 mg/mL) Phase Days 12 (tolerance) Daily dose 2.5 mg once daily Units on U-100 syringe 15 units Volume 0.15 mL Phase Days 3+ (standard) Daily dose 5 mg once daily Units on U-100 syringe 30 units Volume 0.30 mL Phase Split option (BID) Daily dose 2.5 mg twice daily Units on U-100 syringe 15 units each Volume 0.15 mL each These subcutaneous examples come from informal research discussions
Ready to Explore BPC-157
Why It Works: Binds monomeric G-actin and regulates actin polymerization, which drives cell migration, cell growth, and new blood vessel formation (angiogenesis) Supports recruitment of stem/progenitor cells to injured tissue, aiding repair of muscle, tendon, and cardiac tissue in animal studies Modulates inflammatory signaling, tempering excessive inflammation without fully suppressing the healing response Best For: Tendon, ligament, and soft-tissue injuries, plus systemic/full-body recovery support (as opposed to localized, single-site wound repair)
Is there not a supply without preserve
US$ 21.84
US$ 23.20
US$ 21.22
US$ 27.62
US$ 28.75
